Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo

Loading news article.

Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo | WAPE

Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo

Article summary

Related companies

Comments —